08HH Stock Chart & Stats
€2.40
>-€0.01(-0.55%)
At close: 4:00 PM EST
€2.40
>-€0.01(-0.55%)
Day’s Range― - ―
52-Week Range€1.66 - €3.22
Previous CloseN/A
Volume0.00
Average Volume (3M)1.21K
Market Cap
€7.20B
Enterprise Value€84.21K
Total Cash (Recent Filing)€15.29B
Total Debt (Recent Filing)€31.86B
Price to Earnings (P/E)17.2
Beta0.25
Next Earnings
Aug 26, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.61
Shares Outstanding551,940,500
10 Day Avg. Volume2,287
30 Day Avg. Volume1,211
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.82Price Target Upside17.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.16
Revenue Forecast (FY)€4.84B
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA 158% TTM revenue rebound signals recovery from prior declines and strengthening commercial execution. Sustained revenue growth supports scale benefits, funds R&D and commercial expansion, and improves the firm's ability to absorb cost pressure over the next 2–6 months and beyond.
Resilient MarginsNear-50% gross margin with positive net margin reflects product mix and pricing power in pharmaceutical operations. Durable margin levels provide room to reinvest in pipelines and services, supporting profitability stability even if sales mix shifts across segments.
Diversified Business ModelMulti-segment model—manufacturing, distribution, and healthcare services—reduces reliance on any single product or channel. Structural diversification stabilizes cash flows, enables cross-selling, and cushions the firm against shocks in individual therapeutic areas or distribution disruptions.
Bears Say
Weak Cash ConversionLow FCF-to-net-income (~24%) and volatility indicate earnings do not reliably convert to cash. This limits capacity to fund capex, acquisitions, dividends or unexpected needs without raising external financing, raising execution risk if working capital or investments rise.
Moderate LeverageA debt-to-equity near 0.75 with only mid-single-digit ROE implies capital intensity and average returns. Moderate leverage reduces balance sheet flexibility, elevates refinancing and interest risks, and constrains the company's ability to pursue large strategic investments without increasing leverage.
Operating Margin PressureDeclining EBITDA margin and modest EBIT (~7.3%) point to cost or mix headwinds. Persistent margin erosion limits free cash generation and reinvestment capacity, making long-term earnings growth more reliant on structural improvements rather than cyclical revenue gains.
Shanghai Fosun Pharmaceutical (Group) Co News
08HH FAQ
What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was €1.66 and its highest was €3.22 in the past 12 months.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is €7.20B.
When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Aug 26, 2026 which is in 29 days.
How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported €0.043 earnings per share for the quarter, beating the consensus estimate of €0.042 by <€0.001.
Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H does not currently pay dividends.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.05.
How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of €0.043 in its last earnings report, beating expectations of €0.042. Following the earnings report the stock price went down -0.242%.
Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
Currently, no hedge funds are holding shares in DE:08HH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.82 (17.50% Upside)
€2.82 (17.50% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.66%
12-Months-Change
Fundamentals
Return on Equity
2.74%
Trailing 12-Months
Asset Growth
9.40%
Trailing 12-Months
Company Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
08HH Stock 12 Month Forecast
Average Price Target
€2.82
▲(17.50% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―